Skip to main content
SpringerLink
Log in

Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Heart failure with preserved ejection fraction (HFpEF) is problematic to treat, with guidelines for HFpEF management concentrated on treating prevalent comorbidities. The aim of this study is to conduct a systematic review of the economic burden of hospitalisation for HFpEF. We conducted a systematic literature search from 2001, when HFpEF was first identified as an isolated diagnosis, up to July 1, 2020. Databases searched include PubMed, Medline, EMBASE, EBSCO, National Health Service Economic Evaluation and the National Bureau of Economic Research. The primary outcome measure was hospitalisation costs related to HFpEF. A comprehensive search of the literature produced a total of 243 possible studies. A total of nine studies, six from the U.S., met inclusion criteria and were included in this review. All results are presented in United States Dollars (US$) for the financial year 2019. Costs of index (the first) hospitalisation ranged from mean US$8340 up to US$11,366 per admission and increased up to US$31,493 for those with comorbidities. Two studies reported 1-year costs, and these were US$27,174 and US$26,343, respectively. Hospitalisation accounts for approximately 80% of total costs of HFpEF treatment. The results of this systematic review reveal that published costs of HFpEF hospitalisation are limited to nine studies from a comprehensive database search. The costs of an initial HF hospitalisation are significant, and these costs increase when a person with HFpEF presents with comorbidities or other complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ponikowski P, Voors AA, Ankew SD et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200

  2. Shah KS, Xu H, Matsouaka RA et al (2017) Heart failure with preserved, borderline and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol 70(20):2476–2486

    PubMed  Google Scholar 

  3. Bui AL, Horwich TB, Fonarow GC (2010) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8:30–41

    PubMed  PubMed Central  Google Scholar 

  4. Cook C, Cole G, Asaria P et al (2014) The annual global economic burden of heart failure. Int J Cardiol 171:368–376

    PubMed  Google Scholar 

  5. Shafie AA, Tan YP, Ng CH (2018) Systematic review of economic burden of heart failure. Heart Fail Rev 23:131–145

    CAS  PubMed  Google Scholar 

  6. Lesyuk W, Kriza C, Kolominsky-Rabas P (2018) Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc Disord 18(74):1–11

    Google Scholar 

  7. Goyal P, Loop M, Chen L et al (2018) Causes and temporal patterns of 30-day readmissions among older adults hospitalised with heart failure with preserved or reduced ejection fraction. J Am Heart Assoc 7(9):e007785

    PubMed  PubMed Central  Google Scholar 

  8. Bleumink GS, Knetsch AM, Sturkenboom MCJM et al (2004) Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J England 25:1614–1619

    Google Scholar 

  9. Vaduganathan M, Patel RB, Michel A et al (2017) Mode of death in heart failure with preserved ejection fraction. J Am Coll Cardiol 69(5):556–569

    PubMed  Google Scholar 

  10. Nagueh SF, Smiseth OA, Appleton CP et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29(4):277–314

    PubMed  Google Scholar 

  11. Ferrari R, Bohm M, Cleland J et al (2015) Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail 17:665–671

    CAS  PubMed  Google Scholar 

  12. Rocha BML, Falcão LM (2016) Acute decompensated heart failure: a comprehensive contemporary review on preventing early readmission and post discharge death. Int J Cardiol 223:1035–1044. https://doi.org/10.1016/j.ijcard.2016.07.259

    Article  PubMed  Google Scholar 

  13. Nichols GA, Reynolds K, Kimes TM et al (2015) Comparison of risk of re-hospitalisation, all-cause mortality, and medical care resource utilisation in patients with heart failure and preserved versus reduced ejection fraction. Am J Cardiol 116:1088–1092

    PubMed  Google Scholar 

  14. Ziaeian B, Fonarow GC (2017) Epidemiology and aetiology of heart failure. Nat Rev Cardiol 13(6):368–378

    Google Scholar 

  15. Stalhammar J, Stern L, Linder R et al (2014) The burden of preserved ejection fraction heart failure in a real-world Swedish patient population. J Med Econ 17(1):43–51

    PubMed  Google Scholar 

  16. Leung AW, Chan CY, Yan B et al (2015) Management of heart failure with preserved ejection fraction in a local public hospital in Hong Kong. BMC Cardiovasc Disord 15:1–12

    Google Scholar 

  17. Gregory DD, Sernak MJ, Konstam MA, Pereira B, Salem D (2003) Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction. Am J Cardiol 92(11):1300–1305

    PubMed  Google Scholar 

  18. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJV (2012) What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-Preserved, and I-PRESERVED? J Am Coll Cardiol 60(23):2349–2356

    PubMed  Google Scholar 

  19. Larg A, Moss RJ (2011) Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics 29(8):653–671

    PubMed  Google Scholar 

  20. Luhnen M, Prediger B, Neugebauer E et al (2017) Systematic reviews of health economic evaluations: a protocol for systematic review of characteristics and methods applied. Syst Rev 6:238–250

    PubMed  PubMed Central  Google Scholar 

  21. Husereau D, Drummond M, Petrou S et al (2013) Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 16(2):231–250

    PubMed  Google Scholar 

  22. Shaya F, Mullins C, Wong W (2002) Incidence versus prevalence modeling in pharmacoeconomics. Expert Rev Pharmacoeconomics Outcomes Res 2(5):435–442

    Google Scholar 

  23. Shemilt I, Thomas J, Morciano M (2010) A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy 6(1):51–59

    Google Scholar 

  24. Fatoye F, Wright J, Gebrye T (2020) Cost-effectiveness of physiotherapeutic interventions for low back pain: a systematic review. Physiotherapy 108:98–107

    CAS  PubMed  Google Scholar 

  25. Deeks J, Dinnes J, D'Amico R et al (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7(27)

  26. Ziaeian B, Heidenreich P A, Xu H et al (2018) Medicare expenditures by race/ethnicity after hospitalization for heart failure with preserved ejection fraction. JACC: Heart Fail 6(5):388-397

  27. Murphy TM, Waterhouse DF, James S et al (2017) A comparison of HFrEF vs HFpEF clinical workload and cost in the first year following hospitalization and enrolment in a disease management program. Int J Cardiol 232:330–335

    CAS  PubMed  Google Scholar 

  28. Doshi R, Patel H, Shah P (2018) Pulmonary artery catheterisation use and mortality in hospitalizations with HFrEF and HFpEF: a nationally representative trend analysis from 2005 to 2014. Int J Cardiol 269:289–291

    PubMed  Google Scholar 

  29. Doshi R, Patel K, Gupta N et al (2019) Characteristics and in-hospital outcomes of hospitalizations with heart failure with reduced or preserved ejection fraction undergoing percutaneous coronary intervention. Irish JMed Sci 188:791–799

    Google Scholar 

  30. Olchanski N, Vest AR, Cohen JT, DeNofrio D (2020) Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes. Cardiovasc Endocrinol Metabolism 9(1):17–23

    Google Scholar 

  31. Olchanski N, Vest AR, Cohen JT, DeNofrio D (2020) Two-year outcomes and cost for heart failure patients following discharge from the hospital after an acute heart failure admission. Int J Cardiol 307:109–113

    PubMed  Google Scholar 

  32. Olchanski N, Vest AR, Cohen JT, Neumann PJ, DeNofrio D (2018) Cost comparison across heart failure with reduced and preserved ejection fraction: analyses of inpatient decompensated heart failure admission. Int J Cardiol 261:103–108

    PubMed  Google Scholar 

  33. Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz H, Di Tanna G-L (2020) A systematic review of medical costs associated with heart failure in the USA (2014–2020). PharmacoEconomics 38:1219–1236

    PubMed  PubMed Central  Google Scholar 

  34. Caughey MC, Sueta CA, Stearns SC, Shah, AM, Rosamond WD, Chang PP (2018) Recurrent acute decompensated heart failure admissions for patients with reduced versus preserved ejection fraction (from the Atherosclerosis Risk in Communities Study). Am J Cardiol 122(1):108-114

  35. Cheng RK, Cox M, Neely ML et al (2014) Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 168(5):721–730

    PubMed  Google Scholar 

  36. Loop MS, Van Dyke MK, Chen L et al (2016) Comparison of length of stay, 30-day mortality, and 30-day readmission rates in Medicare patients with heart failure and with reduced versus preserved ejection fraction. Am J Cardiol 118(1):79–85

    PubMed  PubMed Central  Google Scholar 

  37. Dunlay SM, Redfield MM, Weston SA et al (2009) Hospitalisations after a heart failure diagnosis a community perspective. J Am Coll Cardiol 54(18):1695–1702

    PubMed  PubMed Central  Google Scholar 

  38. Ather S, Chan W, Bozkurt B et al (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominately male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59(11):998–1005

    PubMed  PubMed Central  Google Scholar 

  39. Mentz RJ, Kelly JP, von Lueder TG et al (2014) Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 64(21):2281–2293

    PubMed  PubMed Central  Google Scholar 

  40. Kelly JP, Mentz RJ, Mebazaa A et al (2015) Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol 65(16):1668–1682

    PubMed  PubMed Central  Google Scholar 

  41. Bress AP, King JB, Brixner D et al (2016) Pharmacotherapy treatment patterns, outcomes, and health resource utilisation among patients with heart failure with reduced ejection fraction at a U S. academic medical center. Pharmacothepyra 36(2):174–186

    CAS  Google Scholar 

  42. Massie BM, Carson PE, McMurray JJ et al (2008) Irbersartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467

    CAS  PubMed  Google Scholar 

  43. Ahmed A, Rich MW, Fleg JL et al (2006) Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 114:397–403

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Holper EM, Blair J, Selzer F et al (2006) The impact of ejection fraction on outcomes after percutaneous coronary intervention in patients with congestive heart failure: an analysis of the National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry. Am Heart J 151(1):69–75

    PubMed  Google Scholar 

  45. Butler J, Djatche LM, Sawhney B et al (2020) Clinical and economic burden of chronic heart failure and reduced ejection fraction following a worsening heart failure event. Adv Ther 37(9):4015–4032

    PubMed  PubMed Central  Google Scholar 

  46. Fonarow GC, Stevenson LW, Walden JA et al (1997) Impact of a comprehensive heart failure management programme in hospital readmission and function status of patients with advanced heart failure. J Am Coll Cardiol 30(3):725–732

    CAS  PubMed  Google Scholar 

  47. Quach S, Blais C, Quan H (2010) Administrative data have high variation in validity for recording heart failure. Can J Cardiol 26:c306–c312

    Google Scholar 

  48. Khand AU, Shaw M, Gemmel I, Cleland JG (2005) Do discharge codes underestimate hospitalization due to heart failure? Validation study of hospital discharge coding for heart failure. Eur J Heart Fail 7(5):792–797

    PubMed  Google Scholar 

  49. Peterson C, Xu L, Florence C, Grosse SD, Annest JL (2015) Professional fee ratios for US hospital discharge data. Med Care 53:840–849

    PubMed  PubMed Central  Google Scholar 

  50. Long L, Mordi IR, Bridges C et al (2019) Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 1(1):CD003331

Download references

Author information

Authors and Affiliations

  1. School of Science and Technology, University of New England, Armidale, Australia

    Hannah Clark, Melissa Pearson, Tom van der Touw & Neil Smart

  2. School of Commerce, University of Southern Queensland, Toowoomba, Australia

    Rezwanul Rana & Jeff Gow

  3. School of Accounting, Economics and Finance, University of KwaZulu-Natal, Durban, South Africa

    Jeff Gow

Authors
  1. Hannah Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rezwanul Rana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeff Gow
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Melissa Pearson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tom van der Touw
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Neil Smart
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualisation: HC, RR, JG, NS. Data curation: HC, RR, MP, TT. Formal analysis: HC, RR, JG. Methodology: HC, RR, JG. Roles/Writing—original draft: HC, RR, JG. Writing—review and editing: HC, RR, JG, MP, TT, NS.

Corresponding author

Correspondence to Jeff Gow.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Appendix

Appendix

Table 5 Approach of the included studies
Full size table

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Clark, H., Rana, R., Gow, J. et al. Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review. Heart Fail Rev 27, 559–572 (2022). https://doi.org/10.1007/s10741-021-10097-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-021-10097-7

Keywords

Search

Navigation